| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.9 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |